{"entity":{"type":"insider","cik":"0001388406","url":"/insider/0001388406","json_url":"/insider/0001388406.json","name":"Chadwick Jeremy G","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":34,"n_filings":11,"first":"2009-01-06","last":"2026-05-27","span_basis":"filed_date"},"name_variants":[{"name":"Chadwick Jeremy G","source":"filing","n_filings":11,"first_seen":"2009-01-06","last_seen":"2026-05-27"}],"transactions":[{"id":5749624,"accession":"0001193125-26-242266","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001193125-26-242266","line_url":"/filing/0001193125-26-242266","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4279.0,"shares_display":"4,279","price_per_share":81.58344402897873,"price_display":"81.58","price_state":"stated","total_value":349095.557,"total_display":"349,095.56","total_whole":"349,096","shares_owned_after":44618.0,"shares_owned_after_display":"44,618","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-27","filed_date":"2026-05-27","scope":"insider","n_lines":2},{"id":5749621,"accession":"0001193125-26-242266","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001193125-26-242266","line_url":"/filing/0001193125-26-242266","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12905.0,"shares_display":"12,905","price_per_share":79.36412051142968,"price_display":"79.36","price_state":"stated","total_value":1024193.9752,"total_display":"1,024,193.98","total_whole":"1,024,194","shares_owned_after":48848.0,"shares_owned_after_display":"48,848","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-26","filed_date":"2026-05-27","scope":"insider","n_lines":5},{"id":6229900,"accession":"0001193125-26-177400","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193125-26-177400","line_url":"/filing/0001193125-26-177400#line-3","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300.0,"shares_display":"300","price_per_share":90.0,"price_display":"90.00","price_state":"stated","total_value":27000.0,"total_display":"27,000.00","total_whole":"27,000","shares_owned_after":61202.0,"shares_owned_after_display":"61,202","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-22","filed_date":"2026-04-24","scope":"insider"},{"id":6017147,"accession":"0001193125-26-159538","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001193125-26-159538","line_url":"/filing/0001193125-26-159538#line-5","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1300.0,"shares_display":"1,300","price_per_share":90.0,"price_display":"90.00","price_state":"stated","total_value":117000.0,"total_display":"117,000.00","total_whole":"117,000","shares_owned_after":61202.0,"shares_owned_after_display":"61,202","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-15","filed_date":"2026-04-16","scope":"insider"},{"id":6017141,"accession":"0001193125-26-159538","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193125-26-159538","line_url":"/filing/0001193125-26-159538#line-3","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5251.0,"shares_display":"5,251","price_per_share":90.0016,"price_display":"90.00","price_state":"stated","total_value":472598.4016,"total_display":"472,598.40","total_whole":"472,598","shares_owned_after":61202.0,"shares_owned_after_display":"61,202","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-14","filed_date":"2026-04-16","scope":"insider"},{"id":6001809,"accession":"0001193125-26-138371","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001193125-26-138371","line_url":"/filing/0001193125-26-138371","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14640.0,"shares_display":"14,640","price_per_share":85.46215683060109,"price_display":"85.46","price_state":"stated","total_value":1251165.976,"total_display":"1,251,165.98","total_whole":"1,251,166","shares_owned_after":62302.0,"shares_owned_after_display":"62,302","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-01","filed_date":"2026-04-01","scope":"insider","n_lines":2},{"id":6001800,"accession":"0001193125-26-138371","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-138371","line_url":"/filing/0001193125-26-138371#line-2","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7600.0,"shares_display":"7,600","price_per_share":85.3792,"price_display":"85.38","price_state":"stated","total_value":648881.92,"total_display":"648,881.92","total_whole":"648,882","shares_owned_after":61202.0,"shares_owned_after_display":"61,202","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-31","filed_date":"2026-04-01","scope":"insider"},{"id":5847492,"accession":"0001193125-26-124367","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001193125-26-124367","line_url":"/filing/0001193125-26-124367#line-8","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24727.0,"shares_display":"24,727","price_per_share":80.2586,"price_display":"80.26","price_state":"stated","total_value":1984554.4022,"total_display":"1,984,554.40","total_whole":"1,984,554","shares_owned_after":61202.0,"shares_owned_after_display":"61,202","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-25","filed_date":"2026-03-25","scope":"insider"},{"id":5847490,"accession":"0001193125-26-124367","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193125-26-124367","line_url":"/filing/0001193125-26-124367","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":91250.0,"shares_display":"91,250","price_per_share":77.4108023090411,"price_display":"77.41","price_state":"stated","total_value":7063735.7107,"total_display":"7,063,735.71","total_whole":"7,063,736","shares_owned_after":76721.0,"shares_owned_after_display":"76,721","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-23","filed_date":"2026-03-25","scope":"insider","n_lines":5},{"id":5749158,"accession":"0001193125-26-102630","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-26-102630","line_url":"/filing/0001193125-26-102630","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25758.0,"shares_display":"25,758","price_per_share":83.30124033698269,"price_display":"83.30","price_state":"stated","total_value":2145673.3486,"total_display":"2,145,673.35","total_whole":"2,145,673","shares_owned_after":79163.0,"shares_owned_after_display":"79,163","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-11","filed_date":"2026-03-11","scope":"insider","n_lines":3},{"id":5762474,"accession":"0001193125-26-091985","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001193125-26-091985","line_url":"/filing/0001193125-26-091985","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3919.0,"shares_display":"3,919","price_per_share":85.29535274304669,"price_display":"85.30","price_state":"stated","total_value":334272.4874,"total_display":"334,272.49","total_whole":"334,272","shares_owned_after":75318.0,"shares_owned_after_display":"75,318","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-04","filed_date":"2026-03-04","scope":"insider","n_lines":4},{"id":5762465,"accession":"0001193125-26-091985","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-26-091985","line_url":"/filing/0001193125-26-091985","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2039.0,"shares_display":"2,039","price_per_share":88.92674796468857,"price_display":"88.93","price_state":"stated","total_value":181321.6391,"total_display":"181,321.64","total_whole":"181,322","shares_owned_after":77729.0,"shares_owned_after_display":"77,729","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-02","filed_date":"2026-03-04","scope":"insider","n_lines":3},{"id":5197808,"accession":"0000950170-25-076993","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-076993","line_url":"/filing/0000950170-25-076993#line-1","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2575.0,"shares_display":"2,575","price_per_share":29.2954,"price_display":"29.30","price_state":"stated","total_value":75435.655,"total_display":"75,435.66","total_whole":"75,436","shares_owned_after":66420.0,"shares_owned_after_display":"66,420","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-23","filed_date":"2025-05-23","scope":"insider"},{"id":4790890,"accession":"0000950170-25-031147","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-031147","line_url":"/filing/0000950170-25-031147","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1383.0,"shares_display":"1,383","price_per_share":30.45054902386117,"price_display":"30.45","price_state":"stated","total_value":42113.1093,"total_display":"42,113.11","total_whole":"42,113","shares_owned_after":68052.0,"shares_owned_after_display":"68,052","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-03","filed_date":"2025-03-03","scope":"insider","n_lines":2},{"id":2895344,"accession":"0000950170-24-063947","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-063947","line_url":"/filing/0000950170-24-063947#line-1","is_derivative":false,"issuer_cik":"0001388406","issuer_name":"Kymera Therapeutics, Inc.","issuer_ticker":"KYMR","issuer_name_source":null,"issuer_url":"/issuer/0001388406","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Chief Operating Officer)","role_mark":"O","role_mark_label":"Officer (Chief Operating Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Operating Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2575.0,"shares_display":"2,575","price_per_share":34.9921,"price_display":"34.99","price_state":"stated","total_value":90104.6575,"total_display":"90,104.66","total_whole":"90,105","shares_owned_after":44183.0,"shares_owned_after_display":"44,183","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-23","filed_date":"2024-05-23","scope":"insider"},{"id":5856496,"accession":"0001179110-09-000611","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-09-000611","line_url":"/filing/0001179110-09-000611#line-1","is_derivative":false,"issuer_cik":"0001157601","issuer_name":"SYNTA PHARMACEUTICALS CORP","issuer_ticker":"SNTA","issuer_name_source":null,"issuer_url":"/issuer/0001157601","owner_cik":"0001388406","owner_name":"Chadwick Jeremy G","owner_display_name":"Chadwick Jeremy G","owner_url":"/insider/0001388406","role":"Officer (Sr. VP, Pgm Mgmt and Clin Ops)","role_mark":"O","role_mark_label":"Officer (Sr. VP, Pgm Mgmt and Clin Ops)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr. VP, Pgm Mgmt and Clin Ops","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4573.0,"shares_display":"4,573","price_per_share":6.2049,"price_display":"6.20","price_state":"stated","total_value":28375.0077,"total_display":"28,375.01","total_whole":"28,375","shares_owned_after":15853.0,"shares_owned_after_display":"15,853","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-01-05","filed_date":"2009-01-06","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":34,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":34,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":34},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001815442","name":"Kymera Therapeutics, Inc.","url":"/issuer/0001815442","role":"Officer (Chief Operating Officer)","n_filings":10,"first_seen":"2024-05-23","last_seen":"2026-05-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001157601","name":"SYNTA PHARMACEUTICALS CORP","url":"/issuer/0001157601","role":"Officer (Sr. VP, Pgm Mgmt and Clin Ops)","n_filings":1,"first_seen":"2009-01-06","last_seen":"2009-01-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001388406","retrieved_at":"2026-08-26T13:36:30+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}